CD38 and B-cell chronic lymphocytic leukemia: Therefore, our real-life results suggested that targeted therapies could be more effective than standard chemotherapy in both CD38+ and CD38- CLL patients, because of more selective BTKi and BCL2i pro-apoptotic effects on downstream signaling in neoplastic cells.